<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53061">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02415413</url>
  </required_header>
  <id_info>
    <org_study_id>GEM-CESAR</org_study_id>
    <nct_id>NCT02415413</nct_id>
  </id_info>
  <brief_title>Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma</brief_title>
  <official_title>A Study of Carfilzomib, Lenalidomide and Dexamethasone (KRd) Plus High-dose Therapy With Melphalan and Autologous Stem Cell Transplantation, Followed by Consolidation With KRd, and Maintenance With Lenalidomide and Dexamethasone in Patients Under 65 Years With High Risk Smoldering Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Onyx Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients included in the study will receive induction treatment during 6 months, followed by
      receive high-dose therapy followed by peripheral blood stem cell transplantation.

      Approximately 3 months after peripheral blood stem cell transplantation patients will
      receive consolidation treatment during 2 months.

      Subsequently patients will start maintenance treatment during 24 months. Therefore, the
      total duration of the treatment will be approximately 36 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is a multicenter Phase II study designed to evaluate the efficacy and
      toxicity of an intensive therapeutic approach in 90 patients with asymptomatic high risk
      multiple myeloma (SMM).

        1. - Patients will receive an induction treatment consisting of 6 cycles of carfilzomib,
           lenalidomide and low-dose dexamethasone (KRd): patients will receive carfilzomib 20-36
           mg/m2 IV on days 1, 2, 8, 9, 15 and 16; with oral lenalidomide 25 mg daily on days
           1-21, subsequently there will be a rest period of a week (from day 22 to day 27).
           Moreover, oral dexamethasone 40mg daily will be administered weekly (days 1, 8, 15 and
           22).

        2. - Following the induction treatment, patients will receive high-dose (200 mg/m2)
           melphalan-based treatment administered via the intravenous route followed by peripheral
           blood stem cell transplantation (HDT-ASCT).

        3. - The consolidation treatment will consist of 2 cycles of KRd, with the same doses and
           scheduled of the induction treatment.

        4. - Maintenance treatment: all patients, without progression to symptomatic multiple
           myeloma or toxicity requiring discontinuation of the trial, will receive maintenance
           treatment during 24 cycles.

      This maintenance treatment comprises the administration of lenalidomide 10mg on days 1-21,
      followed by a rest period of 1 week, with the weekly administration of dexamethasone 20mg.

      Treatment will be administrated until the end of the maintenance, although patients will
      continue in the trial.

      If biological progression is observed following the discontinuation of the treatment,
      lenalidomide and dexamethasone will be reinstituted in order to control the disease again.
      Lenalidomide 10 mg will be administrated on days 1-21 combined with dexamethasone 20mg on
      days 1, 8, 15 and 22. All patients will be monitored for asymptomatic disease progression
      and to collect data regarding on overall survival (OS).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy- Number of Immunophenotypic complete remission rate (Flow-CR) at day +100 after induction and HDT-ASCT</measure>
    <time_frame>4 months</time_frame>
    <description>Number of Immunophenotypic complete remission rate (Flow-CR) at day +100 after induction and HDT-ASCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Number of Response rates after the different parts of the treatment, induction, HDT-ASCT, consolidation and maintenance</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Number of Response rates after the different parts of the treatment, induction, HDT-ASCT, consolidation and maintenance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy- Months to progression free survival</measure>
    <time_frame>60 months</time_frame>
    <description>Months to progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy -Months to overall survival</measure>
    <time_frame>60 months</time_frame>
    <description>Months to overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Smoldering Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Carlizomib lenalidomide and low dose dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction treatment: patients included in the trial will receive an induction treatment for approximately 6 months (6 cycles of carfilzomib, lenalidomide and low dose dexamethasone (KRd)). After the third cycle of KRd, all patients will be mobilized with colony stimulating factor (G-CSF) alone to collect peripheral blood stem cell for the ASCT.
High dose therapy followed by autologous stem cell transplantation: patients will receive melphalan 200 mg/m2 via intravenous followed by autologous stem cell transplantation (HDT-ASCT).
Consolidation treatment: approximately 3 months after the autologous stem cell transplantation, patients will receive consolidation treatment for 2 months (2 cycles of carfilzomib, lenalidomide and low dose dexamethasone (KRd)).
Maintenance treatment: subsequently they will start a maintenance treatment that will be administered for approximately 24 months (24 cycles of lenalidomide and low dose dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carfilzomib</intervention_name>
    <arm_group_label>Carlizomib lenalidomide and low dose dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <arm_group_label>Carlizomib lenalidomide and low dose dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>Carlizomib lenalidomide and low dose dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <arm_group_label>Carlizomib lenalidomide and low dose dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In the investigator's opinion, the patient must be able to fulfill all the clinical
             trial requirements.

          -  The patient must voluntarily sign the informed consent before any study procedure
             that is not part of the standard of care for these patients is performed, with the
             patient's knowledge that he/she may withdraw from the study at any time, without
             prejudice to his/her future care.

          -  Age older than 18 and younger than 65 years and candidates to receive high-dose
             therapy and autologous stem cell transplantation.

          -  The patient must be diagnosed with smoldering multiple myeloma at high risk of
             progressing to symptomatic multiple myeloma, or at ultra high risk of progression to
             symptomatic disease, defined by:

          -  smoldering multiple myeloma at high risk of progression to symptomatic disease:

        Bone marrow infiltration with plasma cells (PCs) greater than or equal 10% and presence of
        a monoclonal component, immunoglobulin G (IgG) greater than3 g/dL or IgA greater than 2
        g/dL or Bence Jones proteinuria greater than 1 g/24h and absence of lytic lesions,
        hypercalcemia, renal failure (creatinine less than 2 mg/dL) and anemia (hemoglobin greater
        than 10 gr/dL or not 2 gr/dL below the lower limit of normal).

        Bone marrow infiltration with PCs greater than or equal 10% OR IgG greater than 3 g/dL or
        immunoglobulin A (IgA) greater than 2 g/dL or Bence Jones proteinuria greater than 1g/24h
        (but not both together) and always in the absence of lytic lesions, hypercalcemia, renal
        failure and anemia. These patients may be included in the study if they meet the following
        additional criteria: A percentage of phenotypically aberrant plasma cells (PCs) within the
        bone marrow (BM) PC compartment (aPC/ BM PC) greater than or equal 95% and
        immunoapheresis, defined as a reduction in the levels of 1 or 2 immunoglobulin (Igs) of
        more than 25% compared with the normal values of the corresponding Ig.

        - smoldering multiple myeloma at ultra high risk of progression to symptomatic disease:

        Presence of more than 1 focal lesion in MRI (ideally whole body MRI).

        Infiltration in the BM equal or higher than 60%.

        Ratio of involved/uninvolved serum Friend leukemia cell (FLC) higher than 100.

          -  The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status
             less than 2.

          -  The patient must be able to attend the scheduled visits.

          -  Women of childbearing potential must have a negative pregnancy test (serum or urine)
             within the 14 days before the starting the study drug. In addition, sexually active
             women must agree to use contraceptive methods (hormone contraceptives [oral,
             injectable or implanted], tubal ligation, intrauterine device, barrier contraceptives
             with spermicide or have a vasectomised partner) while receiving the study drug. Women
             of childbearing potential must agree to undergo pregnancy tests every 4 weeks while
             receiving the study drug (every 14 days for women with irregular menstrual cycles)
             and 4 weeks after the last dose of study drug.

        Exclusion Criteria:

          -  Any physical condition or psychiatric disorder that would prevent the patient from
             signing or understanding the informed consent form.

          -  Previous treatment for smoldering multiple myeloma.

          -  Pregnancy or breastfeeding.

          -  Presence of lytic lesions, anemia, renal failure or hypercalcemia.

          -  Any of the following laboratory abnormalities:

        Absolute neutrophil count (ANC) less than 1,000/mm3

        Platelet count less than 75,000/mm3.

        Serum GOT or glutamic pyruvic transaminase (GPT) greater than 3 x upper limit of normal

        Serum total bilirubin greater than 2 x upper limit of normal

          -  Prior history of neoplasm other than multiple myeloma (except for basal cell or
             squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast)
             unless the patient has been disease-free for &gt; 5 years.

          -  Major surgery within 4 weeks before inclusion in the study.

          -  Known active infection by human acquired immunodeficiency virus, B or C hepatitis
             virus.

          -  Any investigational drug within 30 days before inclusion in the study.

          -  Acute active infection requiring treatment (systemic antibiotics, antivirals, or
             antifungals) within 14 days prior to enrolment.

          -  Unstable angina or myocardial infarction within 6 months prior to enrollment, New
             York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina,
             history of severe coronary artery disease, severe uncontrolled ventricular
             arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia
             or Grade 3 conduction system abnormalities unless subject has a pacemaker.

          -  Uncontrolled hypertension or uncontrolled diabetes.

          -  Significant neuropathy (Grades 3?4, or Grade 2 with pain) within 14 days prior to
             enrollment.

          -  Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize
             carfilzomib).

          -  Contraindication to any of the required concomitant drugs or supportive treatments,
             including intolerance to hydration due to pre-existing pulmonary or cardiac
             impairment.

          -  Left ventricular ejection fraction (LVEF) less than 40

          -  Pulmonary hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jesus F San Miguel, Dr</last_name>
    <email>sanmiguel@unav.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>M Victoria Mateos, Dr</last_name>
    <email>mvmateos@usal.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Rosiñol, Dr</last_name>
      <email>LROSINOL@clinic.ub.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Oriol, Dr</last_name>
      <email>aoriol@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Martinez, Dr</last_name>
      <email>rafaelbenigno.martinez@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joaquin Martinez, Dr</last_name>
      <email>jmarti01@med.ucm.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Lopez, Dr</last_name>
      <email>jljimenez@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe De Arriba, Dr</last_name>
      <email>Farriba@um.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Pilar González, Dr</last_name>
      <email>anapilargonzalez@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesús Fernando San Miguel, Dr</last_name>
      <email>sanmiguel@unav.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Son Llàtzer</name>
      <address>
        <city>Plama de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Bargay, Dr</last_name>
      <email>jbargay@hsll.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Victoria Mateos, Dr</last_name>
      <email>mvmateos@usal.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General de Segovia</name>
      <address>
        <city>Segovia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose M Hernandez, Dr</last_name>
      <email>jhernandezma@saludcastillayleon.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Ángel Álvarez, Dr</last_name>
      <email>mangel.alvarez.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose A Perez, Dr</last_name>
      <email>josea.perez.simon.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Teodoro Hernández, Dr</last_name>
      <email>mthernan@ull.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Isabel Teruel, Dr</last_name>
      <email>ateruelc@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Doctor Peset</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier de la Rubia, Dr</last_name>
      <email>delarubia_jav@gva.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Palomera, Dr</last_name>
      <email>lpalomera@salud.aragon.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 10, 2016</lastchanged_date>
  <firstreceived_date>March 29, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoldering multiple myeloma</keyword>
  <keyword>Carfilzomib</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Melphalan</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Autologous stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
